Welcome to the Adempas® website Take a different path

Adempas® (riociguat) is a soluble guanylate cyclase (sGC) stimulator, the first member of a distinct class of compounds, discovered and developed by Bayer as an oral treatment to target a key molecular mechanism underlying pulmonary hypertension (PH).1,2

Riociguat is approved to treat different types of PH in adults with:

  • inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
  • persistent or recurrent CTEPH after surgery to improve exercise capacity
  • pulmonary arterial hypertension (PAH with WHO functional class II to III, to improve exercise capacity), idiopathic or PAH associated with connective tissue diseases.1-3

It is the first drug demonstrating robust and sustained clinical efficacy in two separate PH groups.1,2,11-14

PH is a severe, progressive, and life-threatening disorder of the lungs and heart characterized by elevated blood pressure in the pulmonary arteries, which can lead to right heart failure and death if left untreated.6,7 There are five types of PH; each can affect the patient in a different way and every patient may have a different etiology of PH.8-10

Adempas® has a dual mode of action – directly stimulating sGC independently of endogenous nitric oxide (NO) and also facilitating the binding of any remaining endogenous NO to sGC .1,2,15 Patients with CTEPH and PAH are often nitric oxide deficient; this results in sGC being under-stimulated and is associated with a poor prognosis.16-18 For patients with CTEPH and PAH, sGC stimulation is fundamental for providing treatment success and helping to regulate vascular tone, proliferation and inflammation.16-18

Disclaimer: Please refer to your country’s specific Adempas® label and prescribing information, as they can differ from the Adempas® Expanded Company Core Data Sheet used to reference this global website.

References:
1. Ghofrani HA et al. Future Cardiol. 2010;6:155–66. 2. Grimminger F et al. Eur Respir J. 2009;33:785–92. 3. Ghofrani HA et al. N Engl J Med. 2013;369:319–29. 4. Ghofrani HA et al. N Engl J Med. 2013;369:330–40. 5. Bayer AG. Adempas® Expanded Company Core Data Sheet (Version 05). May 2017. 6. Rosenkranz S. Clin Res Cardiol. 2007;96:527–41. 7. Macchia A et al. Am Heart J. 2007;153:1037–47. 8. Galiè N et al. Eur Heart J 2016;37:67–119. 9. Ali JM et al. Hosp Pract (1995). 2012;40:71–9. 10. Armstrong I et al. BMJ Open. 2012;2:e000806. 11. Halank M et al. Respir Med 2017;128:50–6. 12. Simonneau G et al. Eur Respir J 2015;45:1293–1302. 13. Simonneau G et al. Lancet Respir Med 2016;4:372–80. 14. Ghofrani HA et al. Lancet Respir Med 2016;4:361–71. 15. Simmoneau G et al. ERJ Express. Published on-line ahead of print, November 13, 2014 16. Kielstein JT et al. Arterioscler Thromb Vasc Biol 2005; 25: 1414-18. 17. Skoro-sajer N et al. Am J Respir Crit Care Med 2007; 176: 1154-60. 18. Stasch J-P et al. Circulation 2011; 123: 2263-73.